HC Surgical Specialists Ltd (SG:1B1)
SGX:1B1
Top Page
HC Surgical Specialists Ltd
(SGX:1B1)
Select Model
Select Model
Rating:74Outperform
Price Target:
S$0.40
â–²(10.56% Upside)
Action:UpgradedDate:03/24/26
The score is driven primarily by strong financial quality (very high margins and a de-risked balance sheet) and very attractive valuation (low P/E and high dividend yield). Offsetting these positives are weak recent growth trends and muted technical momentum, which limit the overall rating.
Positive Factors
High Profitability & Margins
Consistently very high gross margins (mid-80%) and unusually strong operating/net margins (~47%/~44%) indicate a defensible cost structure and pricing power in endoscopic services. This supports durable cash generation and margin resilience even if volumes moderate.
Negative Factors
Sharp Revenue Decline
An almost 100% reported revenue decline signals a material collapse in top-line activity or a reporting base effect; persistent or structural top-line weakness undermines the sustainability of margins, reduces scale benefits, and threatens long-term earnings durability.
Read all positive and negative factors
Positive Factors
Negative Factors
High Profitability & Margins
Consistently very high gross margins (mid-80%) and unusually strong operating/net margins (~47%/~44%) indicate a defensible cost structure and pricing power in endoscopic services. This supports durable cash generation and margin resilience even if volumes moderate.
Read all positive factors
HC Surgical Specialists Ltd (1B1) vs. iShares MSCI Singapore ETF (EWS)
Market Cap
S$56.91M
Dividend Yield3.37%
Average Volume (3M)50.29K
Price to Earnings (P/E)5.2
Beta (1Y)0.04
Revenue Growth1.58%
EPS Growth115.29%
CountrySG
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.03
Shares Outstanding156,309,900
10 Day Avg. Volume16,820
30 Day Avg. Volume50,290
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.09
Price to Sales (P/S)2.29
P/FCF Ratio6.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HC Surgical Specialists Ltd Business Overview & Revenue Model
Company Description
HC Surgical Specialists Limited, an investment holding company, provides medical services primarily in Singapore. The company provides endoscopic procedures, including gastroscopies and colonoscopies; and general surgery services with a focus on c...
HC Surgical Specialists Ltd Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
78
Positive
Cash Flow
71
Positive
| Breakdown | May 2024 | May 2023 | May 2022 | May 2021 | May 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 19.11M | 18.81M | 19.08M | 19.31M | 23.47M |
| Gross Profit | 16.11M | 15.96M | 16.45M | 16.67M | 12.86M |
| EBITDA | 10.88M | 7.01M | 5.96M | 9.59M | 9.69M |
| Net Income | 8.44M | 3.85M | 2.92M | 6.38M | 8.00M |
Balance Sheet | |||||
| Total Assets | 27.27M | 27.84M | 31.26M | 30.96M | 36.28M |
| Cash, Cash Equivalents and Short-Term Investments | 5.73M | 8.06M | 10.26M | 6.93M | 11.17M |
| Total Debt | 2.78M | 4.34M | 5.50M | 6.25M | 8.04M |
| Total Liabilities | 6.52M | 13.37M | 19.18M | 19.74M | 25.53M |
| Stockholders Equity | 20.95M | 14.69M | 12.10M | 11.00M | 9.83M |
Cash Flow | |||||
| Free Cash Flow | 6.75M | 6.23M | 6.51M | 6.83M | 10.24M |
| Operating Cash Flow | 7.23M | 6.30M | 7.22M | 7.05M | 10.75M |
| Investing Cash Flow | -444.00K | 2.84M | -1.72M | -1.99M | -811.00K |
| Financing Cash Flow | -9.05M | -7.97M | -6.24M | -9.12M | -5.74M |
HC Surgical Specialists Ltd Technical Analysis
Positive
0.36
Price Trends
0.36
Positive
0.35
Positive
0.33
Positive
Market Momentum
<0.01
Negative
70.19
Negative
90.48
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:1B1, the sentiment is Positive. The current price of 0.36 is above the 20-day moving average (MA) of 0.35, above the 50-day MA of 0.36, and above the 200-day MA of 0.33, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 70.19 is Negative, neither overbought nor oversold. The STOCH value of 90.48 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SG:1B1.
HC Surgical Specialists Ltd Peers Comparison
UnderperformOutperform
Sector (51)
SG:1B1
HC Surgical Specialists Ltd
0.37
0.11
40.68%
SG:1J5
Hyphens Pharma International Ltd.
0.32
0.04
16.67%
SG:40T
ISEC Healthcare Ltd
0.33
-0.05
-12.63%
SG:BFK
Pharmesis International Ltd.
0.36
-0.15
-29.00%
SG:FRQ
Singapore Paincare Holdings Limited
0.09
-0.02
-17.92%
SG:MIJ
Alliance Healthcare Group Ltd.
0.16
0.05
53.47%
HC Surgical Specialists Ltd Corporate Events
HC Surgical Specialists Lifts Half-Year Profit on Investment Gains, Declares Interim Dividend
Jan 13, 2026
HC Surgical Specialists reported revenue of S$9.78 million for the six months ended 30 November 2025, slightly down 1.6% year-on-year, while profit attributable to shareholders rose 17.5% to S$3.97 million and earnings per share increased to 2.59 ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.